JP2021050244A - Anti-fatigue agent - Google Patents
Anti-fatigue agent Download PDFInfo
- Publication number
- JP2021050244A JP2021050244A JP2021001190A JP2021001190A JP2021050244A JP 2021050244 A JP2021050244 A JP 2021050244A JP 2021001190 A JP2021001190 A JP 2021001190A JP 2021001190 A JP2021001190 A JP 2021001190A JP 2021050244 A JP2021050244 A JP 2021050244A
- Authority
- JP
- Japan
- Prior art keywords
- fatigue
- ornithine
- present
- fatigue agent
- vitamin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000002929 anti-fatigue Effects 0.000 title claims abstract description 56
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 52
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims abstract description 46
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims abstract description 41
- 229960003104 ornithine Drugs 0.000 claims abstract description 41
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims abstract description 39
- 239000004480 active ingredient Substances 0.000 claims abstract description 29
- 150000003839 salts Chemical class 0.000 claims abstract description 19
- 229930003451 Vitamin B1 Natural products 0.000 claims abstract description 6
- 229960003495 thiamine Drugs 0.000 claims abstract description 6
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims abstract description 6
- 235000010374 vitamin B1 Nutrition 0.000 claims abstract description 6
- 239000011691 vitamin B1 Substances 0.000 claims abstract description 6
- 229940088594 vitamin Drugs 0.000 claims description 14
- 229930003231 vitamin Natural products 0.000 claims description 14
- 235000013343 vitamin Nutrition 0.000 claims description 14
- 239000011782 vitamin Substances 0.000 claims description 14
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 12
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 10
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 8
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 6
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 6
- 229930003779 Vitamin B12 Natural products 0.000 claims description 6
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 claims description 6
- 229960000304 folic acid Drugs 0.000 claims description 6
- 235000019152 folic acid Nutrition 0.000 claims description 6
- 239000011724 folic acid Substances 0.000 claims description 6
- 235000001968 nicotinic acid Nutrition 0.000 claims description 6
- 229960003512 nicotinic acid Drugs 0.000 claims description 6
- 239000011664 nicotinic acid Substances 0.000 claims description 6
- 235000019163 vitamin B12 Nutrition 0.000 claims description 6
- 239000011715 vitamin B12 Substances 0.000 claims description 6
- 229930003427 Vitamin E Natural products 0.000 claims description 5
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 5
- 235000019165 vitamin E Nutrition 0.000 claims description 5
- 239000011709 vitamin E Substances 0.000 claims description 5
- 229940046009 vitamin E Drugs 0.000 claims description 5
- 229930003448 Vitamin K Natural products 0.000 claims description 4
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims description 4
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 4
- 235000019158 vitamin B6 Nutrition 0.000 claims description 4
- 239000011726 vitamin B6 Substances 0.000 claims description 4
- 235000019168 vitamin K Nutrition 0.000 claims description 4
- 239000011712 vitamin K Substances 0.000 claims description 4
- 150000003721 vitamin K derivatives Chemical class 0.000 claims description 4
- 229940011671 vitamin b6 Drugs 0.000 claims description 4
- 229940046010 vitamin k Drugs 0.000 claims description 4
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 15
- 206010016256 fatigue Diseases 0.000 description 22
- 235000001014 amino acid Nutrition 0.000 description 17
- 229940024606 amino acid Drugs 0.000 description 17
- 150000001413 amino acids Chemical class 0.000 description 17
- 241000196324 Embryophyta Species 0.000 description 16
- 239000000463 material Substances 0.000 description 15
- 241000209094 Oryza Species 0.000 description 14
- 235000013305 food Nutrition 0.000 description 14
- 235000007164 Oryza sativa Nutrition 0.000 description 13
- 235000009566 rice Nutrition 0.000 description 13
- 239000008187 granular material Substances 0.000 description 11
- 235000013361 beverage Nutrition 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 9
- 241000018646 Pinus brutia Species 0.000 description 9
- 235000011613 Pinus brutia Nutrition 0.000 description 9
- 239000002775 capsule Substances 0.000 description 9
- 230000003833 cell viability Effects 0.000 description 9
- 235000003599 food sweetener Nutrition 0.000 description 9
- 210000003098 myoblast Anatomy 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 239000003765 sweetening agent Substances 0.000 description 9
- 239000000284 extract Substances 0.000 description 8
- 229910052500 inorganic mineral Inorganic materials 0.000 description 8
- 239000011707 mineral Substances 0.000 description 8
- 235000010755 mineral Nutrition 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 7
- 235000009508 confectionery Nutrition 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- -1 inorganic acid salts Chemical class 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 230000001603 reducing effect Effects 0.000 description 6
- GGTYBZJRPHEQDG-WCCKRBBISA-N (2s)-2,5-diaminopentanoic acid hydrochloride Chemical compound Cl.NCCC[C@H](N)C(O)=O GGTYBZJRPHEQDG-WCCKRBBISA-N 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000011701 zinc Substances 0.000 description 5
- 229910052725 zinc Inorganic materials 0.000 description 5
- 235000016804 zinc Nutrition 0.000 description 5
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 4
- 108010011485 Aspartame Proteins 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 239000004472 Lysine Substances 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 4
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 4
- MYYIAHXIVFADCU-QMMMGPOBSA-N anserine Chemical compound CN1C=NC=C1C[C@H](NC(=O)CC[NH3+])C([O-])=O MYYIAHXIVFADCU-QMMMGPOBSA-N 0.000 description 4
- 239000000605 aspartame Substances 0.000 description 4
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 4
- 235000010357 aspartame Nutrition 0.000 description 4
- 229960003438 aspartame Drugs 0.000 description 4
- 229920002770 condensed tannin Polymers 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 4
- 235000013922 glutamic acid Nutrition 0.000 description 4
- 239000004220 glutamic acid Substances 0.000 description 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 4
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 4
- 229960000310 isoleucine Drugs 0.000 description 4
- 229960003646 lysine Drugs 0.000 description 4
- PVXPPJIGRGXGCY-DJHAAKORSA-N 6-O-alpha-D-glucopyranosyl-alpha-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@](O)(CO)O1 PVXPPJIGRGXGCY-DJHAAKORSA-N 0.000 description 3
- 108010085443 Anserine Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- SLRNWACWRVGMKD-UHFFFAOYSA-N L-anserine Natural products CN1C=NC(CC(NC(=O)CCN)C(O)=O)=C1 SLRNWACWRVGMKD-UHFFFAOYSA-N 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 206010049565 Muscle fatigue Diseases 0.000 description 3
- 241000210053 Potentilla elegans Species 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000002040 relaxant effect Effects 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- 208000019914 Mental Fatigue Diseases 0.000 description 2
- 235000008585 Pinus thunbergii Nutrition 0.000 description 2
- 241000218686 Pinus thunbergii Species 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000021329 brown rice Nutrition 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000001055 chewing effect Effects 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 235000012149 noodles Nutrition 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 229940106587 pine bark extract Drugs 0.000 description 2
- 235000020741 pine bark extract Nutrition 0.000 description 2
- 235000015067 sauces Nutrition 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- VSIVTUIKYVGDCX-UHFFFAOYSA-M sodium;4-[2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].COC1=CC([N+]([O-])=O)=CC=C1[N+]1=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=NN1C1=CC=C([N+]([O-])=O)C=C1 VSIVTUIKYVGDCX-UHFFFAOYSA-M 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000003867 tiredness Effects 0.000 description 2
- 208000016255 tiredness Diseases 0.000 description 2
- PEYUIKBAABKQKQ-AFHBHXEDSA-N (+)-sesamin Chemical compound C1=C2OCOC2=CC([C@H]2OC[C@H]3[C@@H]2CO[C@@H]3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-AFHBHXEDSA-N 0.000 description 1
- XNWFXTOHNKPYMK-UHFFFAOYSA-N 3,3a,4,5,6,6a-hexahydrocyclopenta[c]dioxole Chemical compound C1OOC2CCCC21 XNWFXTOHNKPYMK-UHFFFAOYSA-N 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 240000006891 Artemisia vulgaris Species 0.000 description 1
- AHLPHDHHMVZTML-SCSAIBSYSA-N D-Ornithine Chemical compound NCCC[C@@H](N)C(O)=O AHLPHDHHMVZTML-SCSAIBSYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 240000002582 Oryza sativa Indica Group Species 0.000 description 1
- 240000008467 Oryza sativa Japonica Group Species 0.000 description 1
- 235000005205 Pinus Nutrition 0.000 description 1
- 241000218602 Pinus <genus> Species 0.000 description 1
- 235000000405 Pinus densiflora Nutrition 0.000 description 1
- 240000008670 Pinus densiflora Species 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000021438 curry Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000021186 dishes Nutrition 0.000 description 1
- PEYUIKBAABKQKQ-UHFFFAOYSA-N epiasarinin Natural products C1=C2OCOC2=CC(C2OCC3C2COC3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-UHFFFAOYSA-N 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 1
- 229940107187 fructooligosaccharide Drugs 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 235000015220 hamburgers Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 235000008446 instant noodles Nutrition 0.000 description 1
- 235000015094 jam Nutrition 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960005337 lysine hydrochloride Drugs 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 239000008268 mayonnaise Substances 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000036997 mental performance Effects 0.000 description 1
- 229910052751 metal Chemical class 0.000 description 1
- 239000002184 metal Chemical class 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000036314 physical performance Effects 0.000 description 1
- 235000010204 pine bark Nutrition 0.000 description 1
- 235000021395 porridge Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 235000012045 salad Nutrition 0.000 description 1
- VRMHCMWQHAXTOR-CMOCDZPBSA-N sesamin Natural products C1=C2OCOC2=CC([C@@H]2OC[C@@]3(C)[C@H](C=4C=C5OCOC5=CC=4)OC[C@]32C)=C1 VRMHCMWQHAXTOR-CMOCDZPBSA-N 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 235000013570 smoothie Nutrition 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 235000013547 stew Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000008256 whipped cream Substances 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 229940120612 zinc gluconate 5 mg Drugs 0.000 description 1
Images
Abstract
Description
本発明は、抗疲労剤に係り、詳しくは、オルニチン又はその塩（以下、単にオルニチン類ということがある）及び特定の他の成分を有効成分とする抗疲労剤に関する。 The present invention relates to an anti-fatigue agent, and more particularly to an anti-fatigue agent containing ornithine or a salt thereof (hereinafter, may be simply referred to as ornithines) and a specific other ingredient as active ingredients.
近年の長時間労働や過度のストレスを受ける状況下においては、肉体的・精神的疲労が蓄積しやすく、これら疲労の疲労改善を目的とした薬剤等の開発が盛んに行われている。 In recent years, under the circumstances of long working hours and excessive stress, physical and mental fatigue tends to accumulate, and drugs and the like for improving the fatigue of these fatigues are being actively developed.
例えば、オルニチンまたはその塩、およびグルタチオンまたはその塩を有効成分として含有する疲労軽減剤（特許文献１）や、特定の構造式で表されるセサミンなどのジオキサビシクロ〔３．３．０〕オクタン誘導体を有効成分とする抗疲労剤（特許文献２）が提案されている。 For example, a fatigue-reducing agent containing ornithine or a salt thereof and glutathione or a salt thereof as an active ingredient (Patent Document 1), or a dioxabicyclo [3.3.0] octane such as sesamin represented by a specific structural formula. An anti-fatigue agent containing a derivative as an active ingredient (Patent Document 2) has been proposed.
本発明の課題は、疲労軽減効果の高い抗疲労剤を提供することにある。 An object of the present invention is to provide an anti-fatigue agent having a high fatigue-reducing effect.
本発明者らは、オルニチンの疲労軽減効果について鋭意調査・研究したところ、オルニチンと特定の他の成分とを組み合わせることにより、高い疲労軽減効果が得られることを見いだし、本発明を完成するに至った。具体的には、オルニチンと、疲労軽減能がほとんどないか、その能力が小さい特定の他の成分を組み合わせることにより、疲労軽減能を相乗的に向上させることができることを見いだした。 The present inventors have diligently investigated and studied the fatigue-reducing effect of ornithine, and found that a high fatigue-reducing effect can be obtained by combining ornithine with a specific other component, leading to the completion of the present invention. It was. Specifically, we have found that by combining ornithine with certain other ingredients that have little or no fatigue-reducing ability, the fatigue-reducing ability can be synergistically improved.
すなわち、本発明は、オルニチン又はその塩と、下記（ａ）〜（ｄ）からなる群より選ばれる少なくとも１種の成分とを有効成分として含有することを特徴とする抗疲労剤に関する。
（ａ）松、及び稲から選ばれる少なくとも１種の植物素材
（ｂ）アスパルテーム、トレハロース、及び還元パラチノースから選ばれる少なくとも１種の甘味剤
（ｃ）グルタミン、グルタミン酸、グリシン、ヒスチジン、イソロイシン、ロイシン、リジン、メチオニン、フェニルアラニン、チロシン、及びアンセリンから選ばれる少なくとも１種のアミノ酸類
（ｄ）ビタミンＢ１、ビタミンＢ６、ビタミンＢ１２、ビタミンＥ、ナイアシン、葉酸、ビタミンＫ、及び亜鉛から選ばれる少なくとも１種のビタミン・ミネラル類
That is, the present invention relates to an anti-fatigue agent, which comprises ornithine or a salt thereof and at least one component selected from the group consisting of the following (a) to (d) as an active ingredient.
(A) At least one plant material selected from pine and rice (b) At least one sweetener selected from aspartame, trehalose, and reduced palatinose (c) Glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, At least one amino acid selected from lysine, methionine, phenylalanine, tyrosine, and anserine (d) At least one selected from vitamin B1, vitamin B6, vitamin B12, vitamin E, niacin, folic acid, vitamin K, and zinc. Vitamins and minerals
本発明の抗疲労剤は、オルニチン又はその塩と（ａ）〜（ｄ）からなる群より選ばれる少なくとも１種の成分とからなる有効成分を添加して得たものであってもよい。 The anti-fatigue agent of the present invention may be obtained by adding an active ingredient consisting of ornithine or a salt thereof and at least one ingredient selected from the group consisting of (a) to (d).
また、本発明の抗疲労剤は、オルニチン又はその塩と他の有効成分との配合質量比が、０．５：１〜７０：１の範囲であることが好ましい。また、錠剤、カプセル剤、粉末剤、顆粒剤、又は液剤であることが好ましい。 Further, in the anti-fatigue agent of the present invention, the compounding mass ratio of ornithine or a salt thereof and another active ingredient is preferably in the range of 0.5: 1 to 70: 1. Further, it is preferably a tablet, a capsule, a powder, a granule, or a liquid.
さらに、本発明は、上記抗疲労剤を摂取させることを特徴とする疲労軽減方法（ただし、医療行為を除く）に関する。 Furthermore, the present invention relates to a fatigue reduction method (excluding medical practice), which comprises ingesting the above-mentioned anti-fatigue agent.
本発明の抗疲労剤によれば、高い疲労軽減効果を得ることができる。 According to the anti-fatigue agent of the present invention, a high fatigue reducing effect can be obtained.
本発明の抗疲労剤は、オルニチン又はその塩と、下記（ａ）〜（ｄ）からなる群より選ばれる少なくとも１種の成分（以下、他成分ということがある）とを有効成分として含有することを特徴とする。 The anti-fatigue agent of the present invention contains ornithine or a salt thereof and at least one component (hereinafter, may be referred to as another component) selected from the group consisting of the following (a) to (d) as an active ingredient. It is characterized by that.
本発明の抗疲労剤は、肉体的な疲労、及び肉体的疲労に起因する精神的疲労を軽減することができるものであり、具体的には、疲労の予防、改善を行うことができる。すなわち、本発明の抗疲労剤を作業前に摂取することにより、摂取後の作業において疲労の発生が抑制される（疲れにくくする）疲労予防効果が得られると共に、作業後に摂取することにより、作業により生じた疲労を改善（回復）する疲労改善効果が得られる。また、睡眠中に筋肉疲労を軽減することにより、睡眠中のリラックス効果が得られる。 The anti-fatigue agent of the present invention can reduce physical fatigue and mental fatigue caused by physical fatigue, and specifically, can prevent or improve fatigue. That is, by ingesting the anti-fatigue agent of the present invention before work, the fatigue prevention effect of suppressing the occurrence of fatigue (making it less tiring) can be obtained in the work after ingestion, and by ingesting it after work, the work A fatigue improving effect for improving (recovering) the fatigue caused by the above can be obtained. In addition, by reducing muscle fatigue during sleep, a relaxing effect during sleep can be obtained.
［オルニチン］
本発明の抗疲労剤の有効成分となるオルニチンとしては、Ｌ−オルニチンであってもよく、Ｄ−オルニチンであってもよいが、Ｌ−オルニチンであることが好ましい。オルニチンは、化学合成により得られたもの、発酵に得られたもの等、その製造方法は問わない。また、オルニチンの塩としては、薬学的に許容される塩であれば特に制限されるものではなく、例えば、無機酸塩、有機酸塩、金属塩を挙げることができる。オルニチンは、医薬品、試薬等として市販されており、これらの市販品を用いることができる。
[Ornithine]
The ornithine to be the active ingredient of the anti-fatigue agent of the present invention may be L-ornithine or D-ornithine, but L-ornithine is preferable. Ornithine may be produced by chemical synthesis, fermentation, or the like, regardless of the production method. The salt of ornithine is not particularly limited as long as it is a pharmaceutically acceptable salt, and examples thereof include inorganic acid salts, organic acid salts, and metal salts. Ornithine is commercially available as a drug, a reagent, etc., and these commercially available products can be used.
［他成分］ [Other ingredients]
（ａ）植物素材
本発明の抗疲労剤においては、オルニチン又はその塩と共に、有効成分として、松、及び稲から選ばれる少なくとも１種の植物素材を用いることが好ましい。
(A) Plant material In the anti-fatigue agent of the present invention, it is preferable to use at least one plant material selected from pine and rice as an active ingredient together with ornithine or a salt thereof.
これらの植物素材は、葉、茎、根、花、実、幹、枝等、植物のいずれの部位であってもよく、植物素材そのもの（乾燥物を含む）の他、その粉砕物、搾汁、抽出物等の植物素材処理物を用いることができる。粉砕物としては、粉末、顆粒等が挙げられる。絞汁や抽出物は、液状であってもよいが、ペースト状や乾燥粉末として用いることもできる。抽出物は、適当な溶媒を用いて抽出することに得ることができ、溶媒としては、例えば、水（熱水）、エタノール、含水エタノールを用いることができる。これらの植物素材は、市販されているものを使用することができる。 These plant materials may be any part of the plant such as leaves, stems, roots, flowers, fruits, trunks, branches, etc. In addition to the plant materials themselves (including dried products), crushed products and juices thereof. , Extracts and other processed plant materials can be used. Examples of the pulverized product include powder, granules and the like. The juice and extract may be liquid, but can also be used as a paste or a dry powder. The extract can be obtained by extracting with an appropriate solvent, and as the solvent, for example, water (hot water), ethanol, or hydrous ethanol can be used. As these plant materials, commercially available ones can be used.
松としては、例えば、フランス海岸松（Ｐｉｎｕｓ Ｍａｒｔｉｍａ）、カラマツ、クロマツ、アカマツ等を挙げることができ、これらの中でも、プロアントシアニジンが豊富に含まれるフランス海岸松（Ｐｉｎｕｓ Ｍａｒｔｉｍａ）が好ましい。本発明の植物素材として用いる部位としては樹皮が好ましく、この松樹皮から得られる抽出物が特に好ましい。この抽出物には、プロアントシアニジンの他、オリゴメリックプロアントシアニジンが高濃度で含まれており、例えば、抽出物の乾燥質量に対してオリゴメリックプロアントシアニジンを２０質量％以上含むものが好ましい。 Examples of the pine include French coastal pine (Pinus Martinma), Japanese black pine, Japanese black pine, Japanese red pine, and the like, and among these, French coastal pine (Pinus Martina) rich in proanthocyanidins is preferable. Bark is preferable as the site used as the plant material of the present invention, and the extract obtained from this pine bark is particularly preferable. In addition to proanthocyanidins, this extract contains oligomeric proanthocyanidins in a high concentration, and for example, those containing 20% by mass or more of oligomeric proanthocyanidins with respect to the dry mass of the extract are preferable.
稲は、イネ科イネ属の植物である。本発明の植物素材として用いる部位としては、玄米の外皮や胚が好ましく、具体的には、玄米を精白する際に副産物として得られる米ぬかを用いることが好ましい。稲の種類としては、特に制限はなく、ジャポニカ種、インディカ種等を挙げることができる。 Rice is a plant of the genus Oryza in the family Gramineae. As the site used as the plant material of the present invention, the exodermis or embryo of brown rice is preferable, and specifically, rice bran obtained as a by-product when milling brown rice is preferably used. The type of rice is not particularly limited, and examples thereof include japonica rice and indica rice.
（ｂ）甘味剤
本発明の抗疲労剤においては、オルニチン又はその塩と共に、有効成分として、アスパルテーム、トレハロース、及び還元パラチノースから選ばれる少なくとも１種の甘味剤を用いることが好ましい。本発明の甘味剤は、甘味を呈するものを意味し、甘味料としての使用目的に限定されない。
(B) Sweetener In the anti-fatigue agent of the present invention, it is preferable to use at least one sweetener selected from aspartame, trehalose, and reduced palatinose as an active ingredient together with ornithine or a salt thereof. The sweetener of the present invention means one that exhibits sweetness, and is not limited to the purpose of use as a sweetener.
（ｃ）アミノ酸類
本発明の抗疲労剤においては、オルニチン又はその塩と共に、有効成分として、グルタミン、グルタミン酸、グリシン、ヒスチジン、イソロイシン、ロイシン、リジン、メチオニン、フェニルアラニン、チロシン、及びアンセリンから選ばれる少なくとも１種のアミノ酸類（塩を含む）を用いることが好ましい。塩としては、例えば、ナトリウム塩、塩酸塩等を挙げることができる。
(C) Amino acids In the anti-fatigue agent of the present invention, at least selected from glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, tyrosine, and anserine as active ingredients together with ornithine or a salt thereof. It is preferable to use one kind of amino acids (including salts). Examples of the salt include sodium salts, hydrochlorides and the like.
（ｄ）ビタミン・ミネラル類
本発明の抗疲労剤においては、オルニチン又はその塩と共に、有効成分として、ビタミンＢ１、ビタミンＢ６、ビタミンＢ１２、ビタミンＥ、ナイアシン、葉酸、ビタミンＫ、及び亜鉛から選ばれる少なくとも１種のビタミン・ミネラル類を用いることが好ましい。なお、本発明のミネラル類としての亜鉛は、亜鉛を含む化合物の形態を含む。
(D) Vitamin / Minerals In the anti-fatigue agent of the present invention, vitamin B1, vitamin B6, vitamin B12, vitamin E, niacin, folic acid, vitamin K, and zinc are selected as active ingredients together with ornithine or a salt thereof. It is preferable to use at least one kind of vitamins and minerals. Zinc as a mineral of the present invention includes the form of a compound containing zinc.
本発明の抗疲労剤は、オルニチン又はその塩と所定の他成分とを含有し、抗疲労に用いられる点において、製品として他の製品と区別することができるものであれば特に制限されるものではなく、例えば、本発明に係る製品の本体、包装、説明書、宣伝物のいずれかに抗疲労の機能がある旨を表示したものが本発明の範囲に含まれる。例えば、医薬品（医薬部外品を含む）や、特定保健用食品、栄養機能食品、機能性表示食品等の所定機関より効能の表示が認められた機能性食品などのいわゆる健康食品や、飼料等を挙げることができる。いわゆる健康食品においては、「続く疲れに」、「毎日の疲れに」、「肉体的、精神的な高いパフォーマンスをサポート」、「疲れの改善」、「ストレスの改善」、「睡眠の改善」、「眠りを良くする」、「疲れやすい方に」等を表示したものを例示することができる。本発明の抗疲労剤は、上記の効果が気になる人であれば性別や年齢に関係なく摂取することができるが、本発明の抗疲労剤の効果をより有効に享受することができることから、疾病者を除く健常者が摂取することが望ましい。また、睡眠中に筋肉疲労を軽減することにより、睡眠中のリラックス効果が得られることから、夜に摂取することが望ましく、睡眠前に摂取することがさらに望ましい。 The anti-fatigue agent of the present invention is particularly limited as long as it contains ornithine or a salt thereof and a predetermined other component and can be distinguished from other products as a product in that it is used for anti-fatigue. However, for example, the scope of the present invention includes a product indicating that any of the main body, packaging, instruction manual, and advertising material of the product according to the present invention has an anti-fatigue function. For example, so-called health foods such as pharmaceuticals (including non-pharmaceutical products), foods for specified health use, foods with nutritional function, foods with functional claims, etc. Can be mentioned. In so-called health foods, "for continuous tiredness", "for daily tiredness", "supporting high physical and mental performance", "improvement of fatigue", "improvement of stress", "improvement of sleep", Examples of those displaying "to improve sleep", "for those who are easily tired", etc. can be exemplified. The anti-fatigue agent of the present invention can be ingested by a person who is concerned about the above effects regardless of gender or age, but the effects of the anti-fatigue agent of the present invention can be enjoyed more effectively. , It is desirable for healthy people except sick people to take it. In addition, by reducing muscle fatigue during sleep, a relaxing effect during sleep can be obtained. Therefore, it is desirable to take it at night, and it is more desirable to take it before sleep.
本発明の抗疲労剤の形態としては、例えば、錠剤、カプセル剤、粉末剤、顆粒剤、液剤、粒状剤、棒状剤、板状剤、ブロック状剤、固形状剤、丸状剤、ペースト状剤、クリーム状剤、カプレット状剤、ゲル状剤、チュアブル状剤、スティック状剤等を挙げることができる。これらの中でも、錠剤、カプセル剤、粉末剤、顆粒剤、液剤の形態が特に好ましい。具体的には、サプリメントや、ペットボトル、缶、瓶等に充填された容器詰飲料や、水（湯）、牛乳、果汁、青汁等に溶解して飲むためのインスタント粉末飲料、インスタント顆粒飲料を例示することができる。これらは食事の際などに手軽に飲用しやすく、また嗜好性を高めることができるという点で好ましい。 The form of the anti-fatigue agent of the present invention includes, for example, tablets, capsules, powders, granules, liquids, granules, rods, plates, blocks, solids, rounds, and pastes. Examples thereof include agents, creams, capsules, gels, chewables, sticks and the like. Among these, the forms of tablets, capsules, powders, granules, and liquids are particularly preferable. Specifically, supplements, packaged beverages filled in PET bottles, cans, bottles, etc., instant powdered beverages for dissolving in water (hot water), milk, fruit juice, green juice, etc., and instant granule beverages. Can be exemplified. These are preferable in that they are easy to drink at the time of meals and can enhance the palatability.
本発明の抗疲労剤におけるオルニチン及び他成分（有効成分）の含有量としては、その効果の奏する範囲で適宜含有させればよい。 The content of ornithine and other components (active ingredients) in the anti-fatigue agent of the present invention may be appropriately contained within the range in which the effect is exhibited.
一般的には、本発明の抗疲労剤が医薬品やサプリメント（錠剤，カプセル剤）の場合には、有効成分が乾燥質量換算で全体の０．０１〜１００質量％含まれていることが好ましく、０．１〜８５質量％含まれていることがより好ましく、０．５〜７０質量％含まれていることがさらに好ましい。 In general, when the anti-fatigue agent of the present invention is a drug or supplement (tablet, capsule), it is preferable that the active ingredient is contained in an amount of 0.01 to 100% by mass in terms of dry mass. It is more preferably 0.1 to 85% by mass, and even more preferably 0.5 to 70% by mass.
本発明の抗疲労剤が容器詰飲料（液剤）である場合には、有効成分が乾燥質量換算で全体の０．０１〜１０質量％含まれていることが好ましく、０．０３〜６質量％含まれていることがより好ましく、０．０５〜４質量％含まれていることがさらに好ましい。 When the anti-fatigue agent of the present invention is a packaged beverage (liquid agent), the active ingredient is preferably contained in an amount of 0.01 to 10% by mass, preferably 0.03 to 6% by mass, in terms of dry mass. It is more preferably contained, and more preferably 0.05 to 4% by mass.
また、本発明の抗疲労剤がインスタント粉末飲料（粉末剤）、インスタント顆粒飲料（顆粒剤）である場合には、有効成分が乾燥質量換算で全体の１〜１００質量％含まれていることが好ましく、５〜９０質量％含まれていることがより好ましく、１０〜８０質量％含まれていることがさらに好ましい。 Further, when the anti-fatigue agent of the present invention is an instant powdered beverage (powder) or an instant granule beverage (granule), the active ingredient may be contained in an amount of 1 to 100% by mass in terms of dry mass. It is preferably contained in an amount of 5 to 90% by mass, more preferably 10 to 80% by mass.
本発明の効果をより有効に発揮させるためには、有効成分が乾燥質量換算で本発明の抗疲労剤全体（水分を除く）の８０％以上含まれていることが好ましく、９０％以上含まれていることがより好ましく、９５％以上含まれていることがさらに好ましく、１００％であることが特に好ましい。さらに、本発明の抗疲労剤が成分（ａ）〜（ｄ）のいずれかを含有する場合、その含有される成分は、本発明における有効成分のみで構成されることが好ましい。すなわち、本発明の抗疲労剤が例えば成分（ａ）（植物素材）を含む場合には、松、稲以外の植物素材を含まないように構成することが好ましい。 In order to exert the effect of the present invention more effectively, it is preferable that the active ingredient is contained in an amount of 80% or more, and 90% or more, of the entire anti-fatigue agent (excluding water) of the present invention in terms of dry mass. It is more preferable that the content is 95% or more, and 100% is particularly preferable. Further, when the anti-fatigue agent of the present invention contains any of the components (a) to (d), it is preferable that the contained component is composed of only the active ingredient in the present invention. That is, when the anti-fatigue agent of the present invention contains, for example, component (a) (plant material), it is preferable to configure the anti-fatigue agent so as not to contain plant materials other than pine and rice.
本発明の抗疲労剤の摂取量としては特に制限はないが、本発明の効果をより顕著に発揮させる観点から、１日当たりの有効成分の摂取量が、１００ｍｇ／日以上となるように摂取することが好ましく、２００ｍｇ／日以上となるように摂取することがより好ましく、３００ｍｇ／日以上となるように摂取することがさらに好ましい。その上限は特に制限されないが、例えば、２ｇ／日であり、好ましくは３ｇ／日である。本発明の抗疲労剤は、1日の摂取量が前記摂取量となるように、１つの容器に、又は例えば２〜３の複数の容器に分けて、1日分として収容することができる。 The intake amount of the anti-fatigue agent of the present invention is not particularly limited, but from the viewpoint of exerting the effect of the present invention more remarkably, the intake amount of the active ingredient per day is 100 mg / day or more. It is preferable, and it is more preferable to take it so as to be 200 mg / day or more, and it is further more preferable to take it so as to be 300 mg / day or more. The upper limit is not particularly limited, but is, for example, 2 g / day, preferably 3 g / day. The anti-fatigue agent of the present invention can be contained in one container or divided into a plurality of containers, for example, 2 to 3 so that the daily intake becomes the above-mentioned intake, and can be contained as one day's worth.
オルニチン類及び他成分の配合質量比としては、乾燥質量換算で、０．５：１〜７０：１の範囲であることが好ましく、０．７５：１〜６０：１の範囲であることがより好ましく、１：１〜６０：１の範囲であることがさらに好ましく、１：１〜５０：１の範囲であることが特に好ましい。オルニチン類及び他成分の配合比が、上記範囲であることにより、本発明の効果をより有効に発揮することができる。 The compounding mass ratio of ornithines and other components is preferably in the range of 0.5: 1 to 70: 1, and more preferably in the range of 0.75: 1 to 60: 1 in terms of dry mass. It is more preferably in the range of 1: 1 to 60: 1, and particularly preferably in the range of 1: 1 to 50: 1. When the blending ratio of ornithines and other components is within the above range, the effects of the present invention can be more effectively exhibited.
本発明の抗疲労剤は、必要に応じて、経口用として許容される添加剤や、有効成分以外の成分を添加して、公知の製剤方法によって製造することができる。 The anti-fatigue agent of the present invention can be produced by a known formulation method by adding an additive that is acceptable for oral use and an ingredient other than the active ingredient, if necessary.
また、本発明の抗疲労剤としては、有効成分を含有する抗疲労用食品の他、食品に対して有効成分を添加して得た抗疲労用食品を挙げることができ、例えば、通常の食品（天然の食品を含む）に比して本発明の有効成分含有量を増加させた食品や、本発明の有効成分を通常含まない食品に対して有効成分を添加したものを挙げることができる。有効成分の添加は、それぞれの成分を別々に添加してもよいし、同時に添加してもよく、また、有効成分以外の他の成分と共に添加してもよい。 Further, examples of the anti-fatigue agent of the present invention include anti-fatigue foods containing an active ingredient and anti-fatigue foods obtained by adding an active ingredient to a food, for example, ordinary foods. Examples thereof include foods in which the content of the active ingredient of the present invention is increased as compared with (including natural foods) and foods in which the active ingredient is added to foods that do not normally contain the active ingredient of the present invention. The active ingredient may be added separately, simultaneously, or together with other ingredients other than the active ingredient.
本発明の抗疲労用食品としては、例えば、炭酸飲料、栄養飲料、果実飲料、乳酸飲料、スムージー、青汁等の飲料；アイスクリーム、アイスシャーベット、かき氷等の冷菓；そば、うどん、はるさめ、中華麺、即席麺等の麺類；飴、キャンディー、ガム、チョコレート、錠菓、スナック菓子、ビスケット、ゼリー、ジャム、クリーム、焼き菓子、パン等の菓子類；かまぼこ、ハム、ソーセージ等の水産・畜産加工食品；加工乳、発酵乳、ヨーグルト等の乳製品；サラダ油、てんぷら油、マーガリン、マヨネーズ、ショートニング、ホイップクリーム、ドレッシング等の油脂及びその加工食品；ソース、醤油等の調味料；カレー、シチュー、親子丼、お粥、雑炊、中華丼、かつ丼、天丼、牛丼、ハヤシライス、オムライス、おでん、マーボドーフ、餃子、シューマイ、ハンバーグ、ミートボール、各種ソース、各種スープ等のレトルトパウチ食品などを挙げることができる。 The anti-fatigue food of the present invention includes, for example, carbonated beverages, nutritional beverages, fruit beverages, lactic acid beverages, smoothies, green juice and other beverages; ice cream, ice sherbets, shaved ice and other cold confectionery; buckwheat, udon, harusame, Chinese Noodles such as noodles and instant noodles; Confectionery such as candy, candy, gum, chocolate, tablet confectionery, snack confectionery, biscuits, jelly, jam, cream, baked confectionery, bread; Dairy products such as processed milk, fermented milk, yogurt; oils and fats such as salad oil, tempura oil, margarine, mayonnaise, shortening, whipped cream, dressing and their processed foods; seasonings such as sauces and soy sauce; curry, stew, parent and child bowl , Porridge, miscellaneous dishes, Chinese bowl, and bowl, tempura bowl, beef bowl, hayashi rice, omelet rice, oden, marbo dough, dumplings, shumai, hamburger, meat balls, various sauces, various soups and other retort pouch foods. ..
本発明の疲労軽減方法としては、上記説明した本発明の抗疲労剤を摂取させることを特徴とするが、医療行為は含まれない。本発明の抗疲労剤は、上記の効果が気になる人であれば性別や年齢に関係なく摂取させることができるが、本発明の抗疲労剤の効果をより有効に享受することができることから、疾病者を除く健常者に摂取させることが望ましい。また、睡眠中に筋肉疲労を軽減することにより、睡眠中のリラックス効果が得られることから、夜に摂取させることが望ましく、睡眠前に摂取させることがさらに望ましい。本発明の方法としては、例えば、レストラン等の飲食店において、本発明の抗疲労用食品を提供することにより、疲労軽減を図る方法を挙げることができる。 The method for reducing fatigue of the present invention is characterized in that the anti-fatigue agent of the present invention described above is ingested, but does not include medical practice. The anti-fatigue agent of the present invention can be ingested by a person who is concerned about the above effects regardless of gender or age, but the effects of the anti-fatigue agent of the present invention can be enjoyed more effectively. , It is desirable to ingest it to healthy people except sick people. In addition, by reducing muscle fatigue during sleep, a relaxing effect during sleep can be obtained. Therefore, it is desirable to take it at night, and it is more desirable to take it before sleep. Examples of the method of the present invention include a method of reducing fatigue by providing the anti-fatigue food of the present invention in a restaurant such as a restaurant.
以下、本発明を実施例に基づき説明する。
［実施例１］
（１）マウス筋芽細胞株Ｃ２Ｃ１２を、５×１０３ｃｅｌｌｓ／ｗｅｌｌとなるよう９６ｗｅｌｌ ｐｌａｔｅへ播種した。
（２）一晩、前培養し、培養上清除去後、下記表１及び表２に示すようにサンプル添加を行った。
Hereinafter, the present invention will be described based on examples.
[Example 1]
(1) Mouse myoblast cell line C2C12 was seeded on a 96-well plate so as to have 5 × 10 3 cells / well.
(2) After pre-culturing overnight and removing the culture supernatant, samples were added as shown in Tables 1 and 2 below.
各サンプルは、以下のように調製した。
各サンプルを５ｍｇ／ｍＬ（もしくは１．２８ｍｇ／ｍＬ）となるよう１０％ＦＢＳ−ＤＭＥＭへ溶解し、１ｈ転倒撹拌後、フィルタリングを行ったものを原液とした。ただし、疎水性サンプルは、５０ｍｇ／ｍＬとなるようＤＭＳＯへ溶解したものを原液とした。
Each sample was prepared as follows.
Each sample was dissolved in 10% FBS-DMEM so as to be 5 mg / mL (or 1.28 mg / mL), stirred for 1 hour, and filtered, and used as the stock solution. However, the hydrophobic sample was prepared as a stock solution dissolved in DMSO so as to have a concentration of 50 mg / mL.
調製した原液を１０％ＦＢＳ−ＤＭＥＭにてさらに希釈し、目的の終濃度の２倍濃度となるよう調整した。疎水性サンプルは、目的の終濃度の２倍濃度かつ１％ＤＭＳＯ−１０％ＦＢＳ−ＤＭＥＭとなるよう調整した。 The prepared stock solution was further diluted with 10% FBS-DMEM to adjust the concentration to twice the desired final concentration. The hydrophobic sample was adjusted to have a concentration twice the desired final concentration and 1% DMSO-10% FBS-DMEM.
オルニチンについては、市販されるＬ−オルニチン塩酸塩を用いた。オルニチンと共に用いる他成分としては、表３〜表６に示す物質を用いた。 For ornithine, commercially available L-ornithine hydrochloride was used. As the other components used together with ornithine, the substances shown in Tables 3 to 6 were used.
（３）サンプル添加より２４時間後、Ｃｅｌｌ Ｃｏｕｎｔｉｎｇ Ｋｉｔ−８を用いて細胞生存率を測定した。この際、ＤＭＥＭ培地：ＷＳＴ−８溶液＝２０：１となるよう試薬調整を行った。 (3) Twenty-four hours after the sample was added, the cell viability was measured using Cell Counting Kit-8. At this time, the reagent was adjusted so that DMEM medium: WST-8 solution = 20: 1.
培養上清除去後、ＰＢＳにて各ｗｅｌｌを１回洗浄し、ＰＢＳを除去した後、上記ＷＳＴ−８調製液を１５０μＬずつ分注した。発色次第（約１５分後）、４５０ｎｍの吸光度を測定した。 After removing the culture supernatant, each well was washed once with PBS, and after removing PBS, 150 μL of the above WST-8 preparation solution was dispensed. As soon as the color was developed (after about 15 minutes), the absorbance at 450 nm was measured.
その結果を表３〜表６、及び図１〜図８に示す。図中の各グラフは、左から、「コントロール（添加なし）」、「オルニチン（Ｏ）の単独添加」、「他成分の単独添加」、「オルニチン＋他成分添加」の結果を表す。また、グラフ下部の説明における数値は、サンプル濃度を示し、例えば、図１の左のグラフの「Ｏ_０．２５」は、オルニチン０．２５（μｇ／ｍＬ）を示す。添加成分の濃度単位は、すべてのグラフにおいて、μｇ／ｍＬである。 The results are shown in Tables 3 to 6 and FIGS. 1 to 8. Each graph in the figure shows the results of "control (without addition)", "single addition of ornithine (O)", "single addition of other components", and "addition of ornithine + other components" from the left. Further, the numerical value in the explanation at the bottom of the graph indicates the sample concentration, and for example, “O_0.25” in the graph on the left of FIG. 1 indicates ornithine 0.25 (μg / mL). The concentration unit of the additive component is μg / mL in all graphs.
松については、フランス海岸松の樹皮の熱水抽出物（乾燥粉末）を用いた。
稲（米ぬか）については、市販品を用いた。
ヨモギについては、生葉の微粉砕末を用いた。
For pine, a hot water extract (dry powder) of the bark of French coastal pine was used.
For rice (rice bran), a commercially available product was used.
For mugwort, finely ground powder of fresh leaves was used.
表３〜表６、及び図１〜図８に示すように、オルニチンと、本発明の特定の他成分とを組み合わせることにより、筋細胞が相乗的に活発化した。したがって、本発明の抗疲労剤によれば、疲労をより有効に軽減することができる。 As shown in Tables 3 to 6 and FIGS. 1 to 8, muscle cells were synergistically activated by combining ornithine with a specific other component of the present invention. Therefore, according to the anti-fatigue agent of the present invention, fatigue can be reduced more effectively.
［実施例２］（錠剤の製造）
下記成分からなるタブレットを製造した。
[Example 2] (Production of tablets)
A tablet consisting of the following ingredients was manufactured.
Ｌ−オルニチン塩酸塩 １３０ｍｇ（オルニチンとして１００ｍｇ）
フラクトオリゴ糖 ２０ｍｇ
松樹皮抽出物 １０ｍｇ
アルギニン ２０ｍｇ
イソロイシン ５ｍｇ
ロイシン ５ｍｇ
リジン ２ｍｇ
ビタミンＥ １ｍｇ
二酸化ケイ素 ３０ｍｇ
シェラック ２０ｍｇ
L-ornithine hydrochloride 130 mg (100 mg as ornithine)
Fructooligosaccharide 20mg
Pine bark extract 10 mg
Arginine 20 mg
Isoleucine 5 mg
Leucine 5 mg
Silicon dioxide 30 mg
Shellac 20 mg
上記錠剤は、一日に５〜１０粒を噛まずに水と共に服用する。 The above tablets are taken with water without chewing 5 to 10 tablets a day.
［実施例３］（カプセル剤の製造）
下記混合物４００ｍｇをソフトカプセルに封入し、カプセル剤を製造した。
[Example 3] (Manufacturing of capsules)
A capsule was prepared by encapsulating 400 mg of the following mixture in soft capsules.
Ｌ−オルニチン塩酸塩 ２６０ｍｇ（オルニチンとして２００ｍｇ）
アルギニン ６０ｍｇ
リジン ８ｍｇ
葉酸 １０ｍｇ
ビタミンＢ１ １０ｍｇ
ナイアシン １０ｍｇ
グリセリン脂肪酸エステル ５ｍｇ
二酸化ケイ素 ３７ｍｇ
L-ornithine hydrochloride 260 mg (200 mg as ornithine)
Arginine 60 mg
Folic acid 10 mg
Vitamin B1 10 mg
Niacin 10 mg
Glycerin fatty acid ester 5 mg
Silicon dioxide 37 mg
上記カプセル剤は、一日に５粒を噛まずに水と共に服用する。 The above capsules are taken with water without chewing 5 capsules a day.
［実施例４］（顆粒剤の製造）
下記成分を混合して常法により顆粒剤（３０００ｍｇ）を製造した。
[Example 4] (Production of granules)
The following components were mixed to prepare granules (3000 mg) by a conventional method.
Ｌ−オルニチン塩酸塩 ２６００ｍｇ（オルニチンとして２０００ｍｇ）
米ぬか抽出物 ２００ｍｇ
グルタミン ６０ｍｇ
グルタミン酸 ４０ｍｇ
ビタミンＢ１２ １０ｍｇ
グルコン酸亜鉛 ５ｍｇ
乳糖 ５０ｍｇ
難消化性デキストリン ２５ｍｇ
ショ糖脂肪酸エステル １０ｍｇ
L-ornithine hydrochloride 2600 mg (2000 mg as ornithine)
Rice bran extract 200mg
Glutamine 60 mg
Glutamic acid 40 mg
Vitamin B12 10 mg
Zinc gluconate 5 mg
Lactose 50 mg
Indigestible dextrin 25 mg
Sucrose fatty acid ester 10 mg
上記顆粒剤は、一日に１包を水などと共に服用する。 The above granules are taken once a day with water or the like.
［実施例５］（液剤の製造）
下記成分からなる液剤（１００ｍＬ）を製造した。
[Example 5] (Production of liquid preparation)
A liquid preparation (100 mL) composed of the following components was produced.
アスパルテーム ５００ｍｇ
トレハロース ４００ｍｇ
Ｌ−オルニチン塩酸塩 ４００ｍｇ
松樹皮抽出物 １００ｍｇ
ナイアシン ６０ｍｇ
葉酸 ５０ｍｇ
ビタミンＣ ５０ｍｇ
ビタミンＢ１２ ３０ｍｇ
クエン酸 ２０ｍｇ
香料 適量
水 残部
Aspartame 500mg
Trehalose 400mg
L-ornithine hydrochloride 400mg
Pine bark extract 100 mg
Niacin 60 mg
Folic acid 50 mg
Vitamin C 50 mg
Vitamin B12 30 mg
Citric acid 20 mg
Fragrance Appropriate amount of water Remaining
本発明の抗疲労剤は、疲労軽減効果を有し、経口剤として用いることができることから、本発明の産業上の有用性は高い。 Since the anti-fatigue agent of the present invention has a fatigue-reducing effect and can be used as an oral agent, the industrial usefulness of the present invention is high.
Claims (1)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021001190A JP2021050244A (en) | 2021-01-07 | 2021-01-07 | Anti-fatigue agent |
| JP2022107500A JP7462338B2 (en) | 2021-01-07 | 2022-07-04 | Anti-fatigue |
| JP2024039547A JP2024061831A (en) | 2021-01-07 | 2024-03-14 | Anti-fatigue |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021001190A JP2021050244A (en) | 2021-01-07 | 2021-01-07 | Anti-fatigue agent |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019129279A Division JP6829487B2 (en) | 2019-07-11 | 2019-07-11 | Anti-fatigue |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022107500A Division JP7462338B2 (en) | 2021-01-07 | 2022-07-04 | Anti-fatigue |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021050244A true JP2021050244A (en) | 2021-04-01 |
| JP2021050244A5 JP2021050244A5 (en) | 2021-06-10 |
Family
ID=75157080
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021001190A Pending JP2021050244A (en) | 2021-01-07 | 2021-01-07 | Anti-fatigue agent |
| JP2022107500A Active JP7462338B2 (en) | 2021-01-07 | 2022-07-04 | Anti-fatigue |
| JP2024039547A Pending JP2024061831A (en) | 2021-01-07 | 2024-03-14 | Anti-fatigue |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022107500A Active JP7462338B2 (en) | 2021-01-07 | 2022-07-04 | Anti-fatigue |
| JP2024039547A Pending JP2024061831A (en) | 2021-01-07 | 2024-03-14 | Anti-fatigue |
Country Status (1)
| Country | Link |
|---|---|
| JP (3) | JP2021050244A (en) |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04320660A (en) * | 1991-04-19 | 1992-11-11 | Shiuramura Shiyoukoukai | Production of corbicula extract |
| JPH07203910A (en) * | 1994-01-19 | 1995-08-08 | Yoshihide Hagiwara | Production of corbicula extract |
| WO2005023021A1 (en) * | 2003-09-02 | 2005-03-17 | Bbk Bio Corporation | Diet food |
| CN101766637A (en) * | 2008-12-31 | 2010-07-07 | 克科 | Composite for disintoxicating and sobering |
| CN101953825A (en) * | 2010-09-25 | 2011-01-26 | 万红贵 | Anti-alcohol composition and application thereof in preparation of health-care products |
| CN103622121A (en) * | 2013-11-13 | 2014-03-12 | 精晶药业股份有限公司 | Solid beverage containing N(2)-L-alanyl-L-glutamine |
| JP2014159381A (en) * | 2013-02-19 | 2014-09-04 | Kyowa Hakko Bio Co Ltd | Ornithine-containing composition for improving body composition |
| JP2015050991A (en) * | 2013-08-05 | 2015-03-19 | 株式会社ニッセン | Health supplement |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5112865B2 (en) * | 2005-06-27 | 2013-01-09 | 協和発酵バイオ株式会社 | Composition for preventing or treating hemoglobinuria or myoglobinuria |
| JP4847829B2 (en) * | 2006-09-25 | 2011-12-28 | 協和発酵バイオ株式会社 | Vinegar corner control method |
| JP5227978B2 (en) * | 2010-01-08 | 2013-07-03 | キリンホールディングス株式会社 | Alcohol-free malt beverage with high flavor ornithine |
| JP5439672B2 (en) * | 2010-01-25 | 2014-03-12 | キリン協和Ｆｄ株式会社 | Instant dried persimmon containing ornithine |
| JP6005453B2 (en) * | 2012-09-14 | 2016-10-12 | 株式会社ダイセル | Composition comprising ornithine and equol |
-
2021
- 2021-01-07 JP JP2021001190A patent/JP2021050244A/en active Pending
-
2022
- 2022-07-04 JP JP2022107500A patent/JP7462338B2/en active Active
-
2024
- 2024-03-14 JP JP2024039547A patent/JP2024061831A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04320660A (en) * | 1991-04-19 | 1992-11-11 | Shiuramura Shiyoukoukai | Production of corbicula extract |
| JPH07203910A (en) * | 1994-01-19 | 1995-08-08 | Yoshihide Hagiwara | Production of corbicula extract |
| WO2005023021A1 (en) * | 2003-09-02 | 2005-03-17 | Bbk Bio Corporation | Diet food |
| CN101766637A (en) * | 2008-12-31 | 2010-07-07 | 克科 | Composite for disintoxicating and sobering |
| CN101953825A (en) * | 2010-09-25 | 2011-01-26 | 万红贵 | Anti-alcohol composition and application thereof in preparation of health-care products |
| JP2014159381A (en) * | 2013-02-19 | 2014-09-04 | Kyowa Hakko Bio Co Ltd | Ornithine-containing composition for improving body composition |
| JP2015050991A (en) * | 2013-08-05 | 2015-03-19 | 株式会社ニッセン | Health supplement |
| CN103622121A (en) * | 2013-11-13 | 2014-03-12 | 精晶药业股份有限公司 | Solid beverage containing N(2)-L-alanyl-L-glutamine |
Non-Patent Citations (4)
| Title |
|---|
| CHIN. J. PHYSIOL., vol. 54, no. 4, JPN6022013282, 2011, pages 247 - 254, ISSN: 0004744749 * |
| MINTEL GNPD, JPN6021026193, May 2015 (2015-05-01), pages 3197041, ISSN: 0004621493 * |
| MINTEL GNPD, JPN6021026195, March 2014 (2014-03-01), pages 2336863, ISSN: 0004621494 * |
| MINTEL GNPD, JPN6021026196, February 2010 (2010-02-01), pages 1446337, ISSN: 0004621495 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024061831A (en) | 2024-05-08 |
| JP7462338B2 (en) | 2024-04-05 |
| JP2022121730A (en) | 2022-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022060571A (en) | Bone fortifier dietary supplements | |
| JP5888574B1 (en) | Blood flow improver | |
| JP6584270B2 (en) | Blood flow improving composition | |
| JP6889356B2 (en) | Blood glucose elevation inhibitory composition | |
| JP6753618B2 (en) | Composition for suppressing increase in triglyceride in blood | |
| JP6841444B2 (en) | Immunostimulant | |
| JP6498629B2 (en) | Food for suppressing blood neutral fat elevation | |
| JP6646369B2 (en) | Anti-fatigue agent | |
| JP6829487B2 (en) | Anti-fatigue | |
| JP6742575B2 (en) | Joint function improving composition | |
| JP2020186264A (en) | In-blood neutral fat increase inhibitory composition | |
| JP6774065B2 (en) | Blood flow improver | |
| JP2017001966A (en) | Blood triglyceride elevation-inhibiting composition | |
| JP2017002009A (en) | Adjuvant | |
| JP2021050244A (en) | Anti-fatigue agent | |
| JP2016216373A (en) | Blood-flow improving agent | |
| JP2017165686A (en) | Liver function improver | |
| JP6838752B2 (en) | Blood flow improving composition | |
| JP7290369B2 (en) | Blood triglyceride elevation suppressing composition | |
| JP6085872B2 (en) | Food for suppressing blood neutral fat elevation | |
| JP2022173468A (en) | Bloodstream ameliorating composition | |
| JP6744673B2 (en) | Joint function improving composition | |
| JP6736137B2 (en) | Retinal protection composition | |
| JP6142269B2 (en) | Composition for inhibiting blood sugar level elevation | |
| JP2023029502A (en) | Blood flow improver |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210107 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210422 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20210422 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210712 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20210720 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210910 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20211022 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20211216 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20220405 |
|
| C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20220704 |
|
| C116 | Written invitation by the chief administrative judge to file amendments |
Free format text: JAPANESE INTERMEDIATE CODE: C116 Effective date: 20220713 |
|
| C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20220713 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231016 |